Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
THE UNIVERSITY OF MANCHESTER INSTITUTE OF CANCER SCIENCES JOB DESCRIPTION Title: Chair in Early Detection Lung Cancer Research Academic Department: Institute of Cancer Sciences Salary: Consultant Salary Scale (dependent upon experience) Responsible to: Director of the Institute of Cancer Sciences (currently Professor Henry Kitchener) and the appropriate Clinical Director at The Christie NHS Foundation Trust Qualifications: PhD (or equivalent), MRCP (or equivalent), FRCPath Tenure of post: Permanent Summary This is an outstanding opportunity for a new appointment for a Chair in Early Detection Lung Cancer Research within the Institute of Cancer Sciences at The University of Manchester and Honorary Consultant Medical Oncologist at The Christie NHS Foundation Trust. The appointment forms part of a global recruitment drive to bring some of the world’s leading cancer experts and their teams to Manchester. Jointly funded by the University and The Christie, this represents an exciting opportunity for Manchester to recruit some of the best international research talent in screening and prevention, personalised cancer therapy, radiotherapy related research, lung cancer, melanoma, women's cancers and haematological oncology. The University of Manchester is the largest single-site university in the UK with an ambition to be in the top 25 universities worldwide; The Christie is the biggest specialised cancer treatment centre in Europe treating over 40,000 patients a year and the first designated comprehensive centre in the UK. These combined strengths have been harnessed through development of a common strategic vision and an investment plan that capitalises on the enormous potential and opportunity especially in translating research into the clinic. The appointee will have expertise in an aspect of translational research relevant to the early detection of lung cancer and a proven track record in his/her field. He/she will be based in the relevant clinical department at The Christie with laboratory space in the Manchester Cancer Research Centre (MCRC) or Paterson buildings, both of which are located on the hospital site, and will work in association with the North West Lung Centre at the University Hospital of South Manchester NHS Foundation Trust. It is anticipated that the appointee will develop and co-ordinate existing and emerging strengths to facilitate a research portfolio that encompasses clinical and translational 1 aspects of early lung cancer and involves novel imaging and aspects of the basic sciences, depending upon the specific interests of the appointee. The post holder will be expected to collaborate with researchers in lung cancer locally and, where relevant, nationally and internationally. He/she will demonstrate the ability to provide scientific leadership and will be expected to contribute to the overall research strategy for Manchester Lung Cancer Research Group in addition to pursuing his/her individual research programme. It is desirable, but not essential, for the post-holder to be a practising clinician. If so, the post is suitable for a clinical academic/clinician scientist with the expectation that clinical workload will be minimal to ensure that the majority of time is dedicated to research activity. Clinical accreditation in either medical or clinical oncology or pathology is preferred but other specialties will be considered such as imaging and respiratory medicine. The University of Manchester values a diverse workforce and welcomes applications from all sections of the community. 2 Contents Page A) Proposed Appointment ............................................................................... 3 B) Details of Appointment .............................................................................. 3 C) Person Specification .................................................................................. 5 D) Job Plan and Indicative Weekly Timetable .................................................... 6 E) Facilities related to the Appointment ........................................................... 7 F) The University of Manchester...................................................................... 8 G) The Christie NHS Foundation Trust ............................................................ 15 H) University Hospital of South Manchester NHS Foundation Trust..................... 18 I) Terms and Conditions of Service (NHS) ..................................................... 19 J) Appendix 1 Medical Oncology Consultant Staff ............................................ 21 K) Appendix 2 Clinical Oncology Consultant Staff ............................................ 22 L) Appendix 3 The Christie NHS Foundation Trust Executive Board .................... 23 3 A) Proposed Appointment This post will be jointly funded by The University of Manchester and The Christie NHS Foundation Trust. Any clinical activities will be based at The Christie site with the final job plan dependent on the precise interests of the successful candidate. It is anticipated that 7.5 PAs of the post would be devoted to research and teaching activities. The nature of the clinical activity would be dependent on the interests of the appointee. The post holder will demonstrate the ability to provide scientific leadership and will be expected to contribute to the overall research strategy for Manchester Lung Cancer Research Group in addition to pursuing his/her individual research programme. Applications will be welcomed from a range of specialties including Clinical and Medical Oncologists, Pathologists, Imaging and Respiratory Medicine. B) Details of Appointment Details of Appointment The person appointed will be part of a stimulating research community that performs to the highest international levels in research and publications and will have access to the excellent research facilities that The University of Manchester offers. The successful candidate will be expected to be able to undertake the following: Research • Conduct research of international quality commensurate with the research priorities of the Institute of Cancer Sciences and publish it in peer-reviewed high impact journals of national/international standing. • Research leadership in respiratory medicine and thoracic oncology • Develop productive research collaborations with other Groups in the Institute of Cancer Sciences and with other Institutes, Schools and Faculties. • Attract, supervise and support postgraduate research students at Masters and Doctoral level in areas of research, teaching and publications. • Establish a research group and make bids for substantial external funding. Develop and lead a programme of scientific excellence relevant to the early detection of lung cancer. • Establish and exploit productive national and international research collaborations and partnerships to further the acquisition of new knowledge. Education • Promote excellence in learning and teaching in the University at undergraduate and postgraduate levels • Play a role in postgraduate training of doctors and other professionals allied to medicine. • Take a leading role in the development of a fellowship programme, including doctoral supervision, in respiratory medicine and thoracic oncology. Management • Assume a prominent role in the development and delivery of Cancer Research UK’s Lung Cancer Centre of Excellence. 4 • • • • • • C) Take an active role (commensurate with experience and skills) in the management of the Institute of Cancer Sciences as required. Participate as a full member of the Institute of Cancer Sciences through Institute activities, meetings, events etc. Provide academic leadership, development, mentoring and career management for junior colleagues. Contribute to the Institute of Cancer Sciences’ strategy documents. Assist in enhancing the international standing and profile of the Institute of Cancer Sciences. Forge relations with the academic sector, the public sector, industry and the community compatible with the University’s external affairs agenda. Person Specification REQUIREMENTS ESSENTIAL DESIRABLE Qualifications MRCP or equivalent and/or FRCPath Certificate of completion of subspecialty training in Medical or Clinical Oncology or other specialty PhD or equivalent Training & Experience Evidence of ability to play a leadership role in teaching, education and mentorship Evidence of wide experience and training in general and oncological medicine and research Demonstrated interest and experience in lung cancer research (respiratory medicine and/or early detection) High impact publications arising from students’ work Excellence as a practicing physician at NHS Consultant level Track record of successful supervision of PhD students and postdoctoral fellows Academic/Research achievements Evidence of ability to provide academic leadership Basic, clinical or translational research experience relevant to main research interests and programme Evidence of major long term peerreviewed funding in this area International research profile including invitations to speak at international conferences Recent articles in high impact peer reviewed publications The ability to initiate, design and supervise clinical research 5 Evidence of ongoing national/international research collaboration Recipient of research award or prize Ability to communicate and collaborate effectively with colleagues in other disciplines Ability to manage substantial research projects Personal Skills Clinical research leadership and people management skills, with the ability to motivate all levels of staff Demonstrable interpersonal skills Evidence of excellent written and oral communication skills Flexible approach to work The ability to work as part of a multi-disciplinary team Good time management skills, with the ability to prioritise and handle competing demands Personal Circumstances D) Reliable work record Living within reasonable travelling distance of The Christie Job Plan and Indicative Weekly Timetable This will be negotiated depending on the clinical interests and amount of clinical work desired by the post holder. ACTIVITY Research, teaching and University administration PAs 7.5 PAs Out-patient clinic and associated clinical administration 1.0 PA Ward round and multidisciplinary meeting relevant to clinical interest of appointee and associated clinical administration Supporting Professional Activity: CPD 1.0 PA One ward round shared with colleagues 0.5 SPA COLLABORATION Wide and multidisciplinary with University and The Christie colleagues Wide and multidisciplinary with University and The Christie colleagues To be determined by clinical interest of appointee To be determined by clinical interest of appointee University and The Christie colleagues 6 AM 9-1 PM 1.305.30 1 2 3 4 5 6 Monday Research (1 PA) Tuesday Research (1 PA) Wednesday Research (1 PA) Research (1 PA) Research (1 PA) Research (1 PA) Thursday Clinic (0.75 PA) and associated Clinical Admin (0.25 PA) Research (0.5 PA) Ward round (0.5 PA) Friday MDT meeting (0.5 PA) SPA: CPD (0.5 PA) Research (1 PA) The clinical component of the job comprises 1 PAs in direct clinical care undertaken in the context of 1 clinic (0.75 PA) and associated clinical administration (0.25 PA). There will also be an MDT meeting (0.5 PA) and a ward round (0.5 PA). In addition, 0.5 SPAs will be undertaken in Supporting Professional Activity: CPD. If the job holder chooses to have a clinical activity, he/she will be expected to see 1-2 new patients and 6-8 follow-up patients per week. There may be up to 2 inpatients at any one time and their care will be supervised by the new appointee, relevant consultant colleagues and associated junior medical staff, including medical oncology trainees allocated to support the job holder. The research and teaching component of the job comprises 7.5 PAs and will involve writing protocols, grant applications and manuscripts for publication, liaising closely with laboratory colleagues, taking part in research meetings, teaching medical undergraduates and postgraduates and supporting relevant university administration. The successful applicant will have access to office space, secretarial and IT support at The Christie. The Christie supports the requirements for continuing medical education (CME) and is committed to providing time and financial support for these activities. In line with Royal College and GMC guidance, the successful candidate will have access to mentoring. Advice with respect to identifying possible mentors will be provided by the Medical Director at The Christie and/or the Director of the Institute of Cancer Sciences. E) Facilities related to the appointment Laboratory Research The successful applicant’s group will be located in the MCRC or Paterson building and will have access to the core experimental facilities of the Cancer Research UK Manchester Institute (see Section F). The Clinical Experimental Pharmacology (CEP) group, led by Professor Caroline Dive, is based at the CR-UK Manchester Institute. It has expanded significantly since its establishment in 2004, reflecting the breadth of its activities - in vitro, preclinical, in vivo and clinical. CEP staff are organised into several teams: PD biomarkers, QA, PK, Clinical Proteomics, Biomarker discovery, in vivo pharmacology and Molecular Pharmacology. Core research themes within CEP are the evaluation of novel therapies that promote apoptosis and those that prevent angiogenesis (in collaboration with Professor Gordon Jayson) and the evaluation of circulating tumour cells (in collaboration with Dr Fiona Blackhall). CEP has established commercial links, including a significant biomarker alliance with AstraZeneca. 7 The MCRC Biobank facility collects research samples from the major hospitals across the Greater Manchester area, including ovarian cancer samples, which can be accessed for research. Also located on The Christie site is the Wolfson Molecular Imaging Centre (Imaging Facilities), which supports over 50 cancer specific imaging research projects. In addition, the facilities associated with the wider University will be available to the post holder. Within the Faculty of Life Sciences (FLS Facilities) this includes further facilities for imaging, biomolecular analysis and bioinformatics. The University Library has the most extensive range of electronic resources of any UK Higher Education Library. Clinical Research Facilities Clinical research and administrative support facilities (research nursing, administrative and secretarial support) will be provided at The Christie and will be centred on the Patient Treatment Centre/Clinical Trials Unit. Trainee support will be provided from the existing pool of core Speciality Trainees and from supernumerary Clinical Research Fellows. The successful applicant will be part of the Manchester Lung Group and the Clinical Pharmacology group, depending on interest. Secretarial and other support The successful candidate will have access to office space, secretarial and IT support at The Christie. Appropriate external CPD will be encouraged and reasonable expenses will be reimbursed by the Trust. F) The University of Manchester http://www.manchester.ac.uk/ Thoracic Oncology at The University of Manchester The Manchester Lung Cancer Research Group is a multidisciplinary team of scientists and clinicians based at The University of Manchester (including the Cancer Research UK Manchester Institute), The Christie and University Hospital of South Manchester (UHSM). The group is committed to improving the care of patients with lung cancer through a multidisciplinary approach - gradually moving away from empirical approaches towards personalised medicine. To that effect, the Group has developed a programme of clinically-relevant basic, translational and clinical research. Research spans early detection, molecular characterisation and the biology of lung cancer with a focus on discovery of novel kinases, biomarkers for the prediction of treatment outcomes, including circulating tumour cell research, and clinical trials (phase I-III) of new agents and regimens, including radiotherapy research and combined modality approaches. Clinical research is facilitated by a large clinical practice within the Greater Manchester Network (~2,200 new patients with lung cancer a year and ~600 lung patients treated with radical radiotherapy). At least 30% of patients treated at The Christie and UHSM are involved in research projects. The group is a top recruiter and leader in clinical trials nationally and internationally. At any one time, 20-30 clinical trials are either in set up, recruiting or recently closed. Facilities also exist within the MCRC Biobank to systematically collect 8 surgical and bronchoscopic samples from all stages of lung cancer - this is allied to high quality clinical data. Cancer Research UK has recognised the potential of lung cancer research in Manchester and, following the successful recruitment of new Lung Cancer Chairs, will be awarded CR-UK Lung Cancer Centre of Excellence status jointly with University College London (UCL). The Manchester-UCL Lung Cancer Centre of Excellence will combine unique and complementary strengths in clinical and translational cancer research between the two sites to create an environment in which basic and clinical lung cancer research of international standing will flourish. The multidisciplinary research themes within the Manchester Lung Cancer Research Group include: • Radiotherapy research in lung cancer • Translational research • Early detection research • Palliative and supportive care research • Personalised medicine exploiting oncogenic drivers Current activities in early detection research include lung-SEARCH (the only national early detection UK trial) and SPECTRAL (optical tissue biopsies to predict lung cancer) trials. Photodynamic therapies are being developed for early lesions (PEARL) and ultrasound approaches for diagnosis and staging (Lung-BOOST). UCL and MCRC host one of the largest banks of pre-invasive longitudinally collected tissues in the world and are elucidating the genomes and epigenomes to compare progressive to regressive lesions. The future strategy is to develop further innovative trials to detect and treat early pre-invasive and invasive disease and will incorporate longitudinal genomic/epigenomic/intra-tumour heterogeneity and gene expression studies into these trials to identify determinants of progression. The Manchester Lung Cancer Research Group is a top recruiting centre in the UK for lung National Cancer Research Network (NCRN) trials. The group also plays a leadership role within the EORTC lung group and the European Thoracic Oncology Platform (ETOP). Thoracic radiation oncology clinical and translational research will be strengthened from 2018 with the introduction of the Proton Beam Therapy Centres in Manchester and UCL, one of the largest collaborations in Europe. The post-holder will benefit from the research strengths present in thoracic oncology research in Manchester. These include the following programmes: • Dr Fiona Blackhall leads the phase I-III clinical trials programme in lung cancer with a focus on personalised medicine and translational research to ID predictive biomarkers for treatment selection. • Dr Paul Lorigan leads the development of early phase clinical trials in small cell lung cancer. • Dr Corinne Faivre-Finn undertakes research into advanced radiotherapy techniques and drug/radiation combinations in the treatment of lung cancer. She is leading three randomised clinical trials in lung cancer and mesothelioma that have the potential to impact on standard of care. • Dr Richard Booton leads a portfolio of trials focussing on early detection in lung cancer. • Dr John Brognard undertakes a programme of research to identify protein kinases involved in cancer for molecular sub classification and the development of novel treatment strategies. 9 • • • • • Professor Caroline Dive has a global reputation for biomarker research. Her research programme focuses on circulating tumour cells in lung cancer (in collaboration with Fiona Blackhall). Dr Daisuke Nonaka undertakes research into the molecular and histological characterisation of novel biomarkers. Professor Catharine West leads the translational biology research group that exploits high throughput technologies to develop molecular profiles that predict the response of cancer patients to radiation therapy. Professors Kaye Williams leads the hypoxia and therapeutics group, which focuses on tumour microenvironment. Professor Ian Stratford has a major research focus in hypoxia and preclinical radiotherapy. The University of Manchester is Britain’s largest and most popular university, with a distinguished history of academic achievement and an ambitious agenda for the future. The University, with income in excess of £780M, has four Nobel Prize winners amongst its current academic staff, and has embarked on an exciting and bold course which aims to make us one of the top 25 universities in the world, as set out in the University’s strategic vision for 2020: Strategic Vision 2020. The University of Manchester was established in 1824, bringing together The Victoria University of Manchester and UMIST to form The University of Manchester. It has an excellent track record in research, as demonstrated by a research power exceeded only by Oxbridge in the RAE 2008 and specifically by the award of two Nobel prizes in physics in 2010. The University’s research strategy can be found here: UoM Research Strategy. The academic structure of The University of Manchester is made up of Faculties and Schools. There are four Faculties and further information about each Faculty and its related Schools can be found here: UoM Faculties and Schools. In the last few years, the University has spent more than £400M transforming the campus and building a world-class environment for outstanding scholars, teachers and internationally acclaimed research teams. This is the largest investment ever seen in UK higher education history. A further £250M investment by 2015 will bring the total spend to more than £650M. Faculty of Medical and Human Sciences www.mhs.manchester.ac.uk The Faculty of Medical and Human Sciences is a leading international centre for research and education in medicine and a spectrum of health-related professions including nursing, midwifery, social work, pharmacy, dentistry, psychology, audiology and speech and language therapy. A major review in 2011/12 led to a new strategy and structure intended to enhance research and teaching performance. A key component of the new approach is the creation of a matrix structure linking five Faculty Schools with six Faculty Institutes. Details of the structure can be found here: FMHS Structure. 10 The objective is to ensure that the Faculty achieves a major international academic profile in each priority area within a period of five years and the strategy focuses research efforts in six priority areas: • Human Development including Women’s and Children’s Health • Cardiovascular Sciences • Cancer Sciences • Inflammation and Repair • Brain, Behaviour and Mental Health • Population and Health Sciences The Faculty has a total income of £210M, around 6,500 undergraduate students and 2,500 postgraduate students. It has strong relationships with outstanding NHS partners, which are critical in achieving our mission. Institute of Cancer Sciences www.cancer.manchester.ac.uk The Institute of Cancer Sciences is one of six Faculty Institutes within the Faculty of Medical and Human Sciences. It comprises five research themed Centres: Haematological Oncology; Paediatric, Teenage and Young Adult Cancer; Personalised Therapy; Radiotherapy Related Research and Women’s Cancer. Research interests span from biomarker studies using clinical proteomics and microarray analyses to clinical trials. The present management team includes: Professor Henry Kitchener Institute Director Professor Tim Illidge Centre Lead for Radiotherapy Related Research Professor Vaskar Saha Centre Lead for Paediatric, Teenage and Young Adult Cancer Professor Paul Townsend Centre Lead for Personalised Therapy Professor John Radford Centre Lead for Haematological Oncology Dr Andrew Clamp Centre Lead for Women’s Cancer The post holder will be a member of the Centre for Personalised Therapy. There are 36 substantive academic members of staff within the Institute, including 25 academic clinicians. The Institute of Cancer Sciences has a first rate publication record in high impact medicine and cancer journals and has a significant research income from industry, research councils and charities. The majority of Institute of Cancer Sciences researchers have laboratory space in one of the University buildings on The Christie site, which provides a focus for cancer research activity - combining an international reputation for cancer research with the largest scale cancer clinical service in the UK. Other activity in the Institute of Cancer Sciences is based either on the University’s Oxford Road site or in key Manchester Academic Health Science Centre (MAHSC) partner sites at Central Manchester University Hospitals NHS Foundation Trust, University Hospital of South Manchester NHS Foundation Trust and Salford Royal NHS Foundation Trust. The large patient base found in Greater Manchester and links to the research network provides major opportunities for the growth of clinical and translational research, a key objective of the Trusts and the University. The Institute of Cancer Sciences plays a key role in taking advantage of this opportunity to seamlessly link basic and clinical science. 11 Cancer Research UK Manchester Institute www.cruk.manchester.ac.uk The Cancer Research UK Manchester Institute is a leading cancer research institute funded by Cancer Research UK (CR-UK), the largest independent cancer research organisation in the world. Research spans the whole spectrum of cancer research, from programmes investigating the molecular and cellular basis of cancer, to those focused on translational research and the development of novel therapeutic approaches and experimental pharmacology. Currently the Institute contains multiple Cancer Research UK-funded basic science and translational science research groups. The programmes span from basic science mechanisms of cell proliferation through to the identification of new biomarkers for novel treatments. The CR-UK Manchester Institute is located in the Paterson building and has excellent laboratory facilities and outstanding core services, including microarrays, confocal microscopy, bioinformatics, histology and access to mass-spectrometry based proteomics. There is also a biological resource unit with expertise in generating transgenic mice as well as tumour implantation studies. A Cancer Research UK funded Drug Discovery Unit was established at the CR-UK Manchester Institute in 2009. Integrating medicinal, computational and synthetic chemistry with in vitro and cellular biology, the Unit investigates novel drug discovery targets in an attempt to provide new chemical entities for the treatment of unmet clinical needs in cancer patients. It has established facilities to enable state-of-the-art biological and clinical target assessment and validation, small molecule drug design and synthesis and the biological evaluation of the resultant compounds. Manchester Academic Health Science Centre www.mahsc.ac.uk The University, and in particular the Faculty of Medical and Human Sciences, is a key member of the Manchester Academic Health Science Centre (MAHSC). Formed in 2008, MAHSC is a Federation of Equal Partners enabled by a Company Limited by Guarantee. The partners involved in the MAHSC are: The University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester Mental Health and Social Care Trust, Salford Primary Care Trust (NHS Salford), Salford Royal NHS Foundation Trust, The Christie NHS Foundation Trust and University Hospital of South Manchester NHS Foundation Trust. MAHSC is one of only five Department of Health designated AHSCs in the UK. The designation is a mark of excellence across research, innovation, education and patient service, and recognition of the potential to excel in translational medicine. MAHSC’s vision is to be a leading global centre for the delivery of innovative applied health research and education into healthcare. As with other AHSCs, MAHSC has a dual role: to act as a beacon of international excellence for the UK and to provide leadership and early adoption for our local health system. This will be delivered via a tripartite approach encompassing: research and innovation; education and training; and clinical service. 12 Manchester Cancer Research Centre www.mcrc.manchester.ac.uk Advances in our understanding of cancer biology together with rapid technology developments provide a unique opportunity to transform cancer care through treatment personalisation. To capitalise on this opportunity, the Manchester Cancer Research Centre (MCRC) was established in January 2006 by The University of Manchester, The Christie and Cancer Research UK - integrating cancer research efforts across the basic, translational and clinical research spectrum. It brings together the expertise, vision and resources of partner organisations that have formidable individual reputations in cancer research and treatment. The partnership harnesses Manchester’s significant strengths to maximise the enormous potential and opportunity, ultimately leading to improvements in treatment that will benefit patients in the city and beyond. The MCRC forms the cancer research arm of the Manchester Academic Health Science Centre (MAHSC). It is also an accredited Cancer Research UK Centre, part of a national framework of 18 Centres of excellence in cancer research. Unprecedented advances in our understanding of cancer biology, coupled with developments in enabling technologies, have provided a unique opportunity to implement personalised medicine for cancer patients. The MCRC is exploiting these opportunities by implementing an integrated personalised medicine strategy - using individual patient’s clinical, genomic and epidemiological characteristics to deliver the most effective first-line treatments, and to modify treatment as the tumours evolve under the selective pressure of treatment. The MCRC’s approach will transform patient care and improve cancer outcomes, achieving sustained responses to treatment. Going beyond the current personalised medicine paradigm, which is largely focussed on late stage patients entering molecularly-targeted drug based therapies, the MCRC aims to implement personalised medicine at diagnosis and all the way through treatment with surgery, radiotherapy and drug therapy. The MCRC is almost uniquely placed within the UK to be in the vanguard of personalised medicine developments, with a proven track record of working together and an impressive staff of outstanding leaders who will deliver our research programmes. These wide ranging innovative and interconnected programmes are supported by a comprehensive platform of facilitating infrastructure and technologies, ensuring that exploratory translational research is taken through the regulatory steps needed for clinical testing and robust demonstration of clinical utility. Few places have the breadth and depth of expertise, the buy-in from all partners, the investment, the infrastructure, and the access to a large and diverse patient population to become internationally leading in this area. A major achievement in 2013 was the successful bid to establish a national cancer imaging research centre that formally links Manchester with the University of Cambridge – the Cancer Research UK/Engineering and Physical Sciences Research Council Cancer Imaging Centre in Cambridge and Manchester. It combines cuttingedge translational research and clinical trials with state-of-the-art imaging, genomics and pre-clinical research. By combining these two locations the CMCIC has access to a large patient population and vital clinical trials infrastructure supported by Cancer Research UK’s Experimental Cancer Research Centres. 13 Cancer Research UK has recognised the potential of lung cancer research in Manchester and, following the successful recruitment of new Lung Cancer Chairs, will be awarded CR-UK Lung Cancer Centre of Excellence status jointly with University College London (UCL). The Manchester-UCL Lung Cancer Centre of Excellence will combine unique and complementary strengths in clinical and translational cancer research between the two sites to create an environment in which basic and clinical lung cancer research of international standing will flourish. Outstanding facilities already exist within the MCRC, however, a new research building is currently under development and will be completed in the summer of 2014. This will allow for the expansion of vital research activities with tremendous potential for future breakthroughs that improve treatment for cancer patients. It will accommodate 250 staff, including 150 scientists whose research will focus entirely on early cancer research that aims to understand how cancer starts, develops and progresses. Working alongside these researchers, The Christie will re-locate 100 clinical trials support staff to the second floor of the building. Researchers in Manchester have access to the MCRC Biobank, which provides scientists with access to a large quantity of high quality biological samples for research purposes. The Biobank provides a centralised resource, collecting samples from five NHS Trusts across the Greater Manchester area. Facilities exist to systematically collect surgical and bronchoscopic samples from all stages of lung cancer and this is allied to high quality clinical data. Within the MCRC, there are a number of biomarker discovery platforms: • Metabolomics - involves the analytical measurements of small molecules within cells and body fluids and these metabolites can act as biomarkers for diagnostics and disease management. There are established metabolomics facilities in the Manchester Institute of Biotechnology (MIB) and Centre for Advanced Discovery and Experimental Therapeutics (CADET). These are mass spectrometry-based metabolomics focusing on untargeted and targeted measurements using GC-MS and LC-MS. Manchester has a long history in metabolomics and was the first to coin this term in 1998. Researchers have also been very active in Metabolomics Standards Initiatives, nomenclature and in data sharing. • Proteomics – the MCRC has established a significant reputation in proteomics. The equipment base, trained multidisciplinary workforce and established protocols enable biomarker discovery and validation projects. These have been applied to lung cancer in collaboration with colleagues in the Cancer Research UK Manchester Institute, University Hospital of South Manchester and The Christie. • Genomics - the Manchester Centre for Genomic Medicine (MCGM) is one of the largest comprehensive integrated clinical and academic centres providing in Europe. With a staff of over 270, it provides a portfolio of services for families with chromosomal and genetic disorders. It has a large programme of clinical and basic cancer genetics studies with major focus on breast and colorectal cancer at present. The PROCAS study of 60,000 women undergoing national breast cancer screening is such an example of the translational research. The MCGM hosts nationally commissioned services for neurofibromatosis types 1 and 2, which supports a stellar research program on schwannoma and meningioma pathogenesis. The clinical laboratory provides molecular testing for a range of somatic mutations including EGFR, ALK translocations KRAS and BRAF. It uses a range of platforms including mutation panel testing by sequenom and next generation sequencing. The MCGM hosts the European Quality assurance Network providing QA to over 1,300 labs worldwide. 14 G) The Christie NHS Foundation Trust www.christie.nhs.uk The Christie NHS Foundation Trust was established in 1901 by charitable donations, as a specialist hospital caring for cancer patients and developing new treatments. It became a Foundation Trust in April 2007, has 30,000 members and a turnover of £183M. It has a green governance rating and a financial risk rating of 4 (good) from Monitor and was rated one of the top 5 hospitals in England by the 2011 staff and inpatient survey. The Christie is the sole provider of radiotherapy and chemotherapy to the 3.2 million people in the Greater Manchester and Cheshire cancer network, which is the largest in England. It also provides highly specialist surgical cancer services to patients across the north west and nationally. In addition, it delivers radiotherapy services from two satellite centres that it runs at the Royal Oldham and Salford Royal hospital sites. Consultants from The Christie visit 8 other hospitals in the network, delivering outpatient services and some chemotherapy treatments. The Christie brings together basic and translational research with NHS service on a single site to deliver new cancer treatments. It is one of the largest cancer centres in Europe, treating more than 40,000 cancer patients a year, and has been elected to the board of the Organisation of European Cancer Institutes (OECI), the umbrella organisation for all the major cancer centres in the EU. The Christie is organised in four clinical management divisions: Networked Services Division includes the Departments of Medical Oncology, Clinical Oncology, Palliative Care, Endocrinology, and Paediatric and Adolescent Oncology. Cancer Centre Services includes Surgery, Anaesthetics, HDU, Haematology, Radiology, Pathology, Pharmacy and Supportive care. In addition, the divisions of Christie Medical Physics and Engineering and Research and Education deliver important components of the comprehensive cancer centre. The Departments of Medical and Clinical Oncology have international reputations for their clinical work. All consultants are site specialised and common treatment policies are developed through the multi-disciplinary Disease Groups (DGs). Links to the cancer units are maintained through a number of peripheral and outreach clinics across the network. The Patient Treatment Centre opened in November 2010 and is a purpose built facility encompassing a dedicated Clinical Trials Unit, an outpatient chemotherapy treatment facility and a private patient facility. Two satellite radiotherapy centres, at Oldham and Salford, enabling increased capacity for treatment and local delivery of treatment, opened in August 2010 and July 2011 respectively. There are plans for The Christie to develop satellite centres in the Pennine Trust and in Salford so that ambulatory care can be delivered locally. The Christie is committed to cancer research. The Research Division has strong links with The University of Manchester, Cancer Research UK and the Manchester Cancer Research Centre. 15 Department of Medical Oncology The Christie Department of Medical Oncology is one of the largest departments of cancer medicine in the NHS with over 20 consultants (see Appendix 1). The major remit of the department is to develop improved methods for cancer patient management. There are both clinical and laboratory scientific research components that are closely integrated with clinical research and service work. The Department has links with Preston Oncology Centre and with the Department of Medical Oncology at Lancaster Royal Infirmary. A good liaison exists between the divisions of Clinical Oncology and Medical Oncology. Many of the clinical protocols are run jointly between the two departments and there are excellent opportunities at Specialist Registrar level to participate in joint teaching programmes. Department of Clinical Oncology The Christie Department of Clinical Oncology provides the largest radiotherapy service in the country with 34 consultants (see Appendix 2), state-of-the-art radiotherapy equipment along with a major research centre - The Wade Centre. The Department provides a service to Greater Manchester and East Cheshire through clinics (mainly weekly) staffed by its consultants in every main town in the area. The department treats around 8,000 patients a year, delivering over 100,000 fractions of radiotherapy. The department was the first in the UK to deliver IMRT (1999) and also the first to use cone beam imaging in clinical practice (2003). Patient Treatment Centre and Early Phase Clinical Trials Unit The dedicated early phase Clinical Trials Unit was established on The Christie site in 2003. The subsequent development of the Clinical Experimental Pharmacology group, GCLP compliant laboratories, the Wolfson Molecular Imaging Centre and the MCRC Biobank have complemented this clinical infrastructure and, over the last 8 years, the Unit has flourished, doubling its research activity to more than 10,000 patient visits annually. It presently supports over 100 clinical trials, recruits over 700 patients per annum to early phase studies and collects over 18,000 biological research samples. A successful Clinical Research Infrastructure bid has allowed a major programme of expansion for clinical trials at The Christie and this has enabled Manchester to become one of the largest centres for early phase clinical trials worldwide. This infrastructure forms part of the Patient Treatment Centre, a £35M development that includes enlarged facilities for clinical and translational research, an outpatient chemotherapy treatment facility, a pharmacy and a private patient facility. The opening of the Patient Treatment Centre in November 2010 reinforced Manchester as one of the premier sites for conducting early phase clinical research world-wide. Associated Departments Haematological Oncology Currently 18 bedded specialist unit for the treatment of haematological malignancies and bone marrow failure. There is a large autologous and allogeneic haematopoietic transplantation programme, performing over 100 procedures annually. Dedicated out-patient and day case facilities include on-site photopheresis access. In March 2014, the department will expand into a new purpose built combined oncology unit. This 31 bedded unit will have increased capacity for the performance 16 of allogeneic transplants and dedicated facilities for the care of teenagers and young adults. Outpatient facilities Routine Medical Oncology clinics are held daily at The Christie for new patients and follow up. There are specialised cancer site-related collaborative clinics and routine outpatient clinics. Specialist nurse facilities Teams of specialist chemotherapy and research nurses work alongside the clinicians. These nurses have special expertise and training in the administration of chemotherapy. Specialist nurses are also trained to insert i.v. long lines, carry out bone marrow aspiration/trephine procedures, operate the cell separators for leukapheresis and provide psychological support and counselling. Other Departments The Department of Histopathology provides a regional cancer service. The Department of Diagnostic Radiology currently has 14 consultants and has two whole body spiral CAT scanners and two MR scanners, in addition to standard radiological and radionucleide imaging facilities. This department provides the regional PET service, is currently undergoing major refurbishment, and by 2015 will have an additional 3T MR scanner plus a second SPECT CT scanner. Further MR and spectral CT will be commissioned for the opening of Proton Therapy Centre by the end of 2018. The Department of Psychological Medicine is involved in collaborative research projects concerning psychological assessment and counselling in the context of clinical trials and is responsible for staff training in aspects of psychological support. Clinical and Laboratory Scientific Research A wide range of clinical research studies are in progress. The breast, lung, lymphoma and GI research groups are major contributors to national and international trials of new treatments. These include Phase I/II and III chemotherapy studies, combined surgery, radiotherapy and chemotherapy studies and patient evaluation studies (staging procedures, psychological assessment etc), strong collaborations with the NCRN clinical subgroups and many pharmaceutical companies. Excellent computer facilities are available within the Medical and Clinical Oncology Division and there is a close association with the Department of Medical Statistics. Data managers are in post to help handle clinical and laboratory research data. Training is given in this important aspect of clinical research. MAHSC Trials Co-ordination Unit (MAHSC CTU) The primary purpose of the MAHSC Trials Co-ordination Unit is to undertake the management and coordination of investigator led clinical trials. The unit provides a wide range of services including; study design protocol development, cost estimates for grant funding applications, study setup, study quality management, study randomisation service, data management and statistical analysis. In November 2007, the MAHSC-CTU achieved full UK CRC trial unit registration; a prerequisite to enable DH/NIHR grant funding opportunities. It is the only such registered unit in the Greater Manchester region. 17 Currently the MAHSC-CTU has a portfolio of 15 managed trials, including major national and international multi centre trials covering over 120 clinical research sites investigating treatment for patients with a range of cancers. The unit has been awarded funds from the HTA, Cancer Research UK and Breakthrough Breast Cancer, totalling over 2.5 million pounds. In 2010, additional pump priming infrastructure funding was awarded by the Christie Charity to facilitate future expansion. H) University Hospital of South Manchester NHS Foundation Trust The Christie and University Hospital of South Manchester (UHSM) are located within 5 miles of each other and together host regional services for the diagnosis, staging and treatment of thoracic malignancy. At UHSM, the North West Lung Centre (NWLC) offers a rapid access clinic responsible for approximately 300 lung cancer and mesothelioma cases each year. It provides diagnostic and staging investigations for lung cancer patients of the Greater Manchester and Cheshire Network, one of the largest in England with ~2,500 cases annually, and has facilities for diagnostic and advanced bronchoscopy including autofluorescence, narrow band imaging, endobronchial ultrasound (linear & radial), pleural ultrasound, medical thoracoscopy, physician stenting, intraluminal brachytherapy and photodynamic therapy. The NWLC will complete the development of a dedicated 3-room bronchoscopy unit in February 2014. It has excellent working relationships with the departments of thoracic pathology and thoracic surgery, which perform approximately 380 lung cancer resections per year. In addition to the Lung Cancer Multi-Disciplinary Team (MDT), UHSM also runs the Specialist Pleural MDT, Network Airway Management MDT and High Risk Surgical MDT. Furthermore the NWLC offers a wide range of systemic therapies for advanced thoracic malignancy including malignant pleural mesothelioma, and adjuvant therapy of surgically resected Non-Small Cell Lung Cancer (NSCLC). The current multidisciplinary thoracic oncology team at UHSM runs a collaborative programme of research, working closely with colleagues at The Christie and The University of Manchester to comprise the MCRC Lung Cancer Research Group. Respiratory Medicine Respiratory medicine at UHSM includes a thoracic oncology group, which focuses on early lung cancer detection and the genomics of preneoplasia, early invasive disease and disease recurrence. There is also a programme of research exploring circulating biomarkers in surgically resected NSCLC. It performs a number of Comprehensive Local Research Network (CLRN) funded studies and has a large research bronchoscopy practice, recruiting over 200 patients a year to clinical trials. In addition, the NWLC has subspecialty clinical and research interests that may facilitate the research ambitions of the post holder in airways disease, cystic fibrosis and non-CF bronchiectasis, interstitial lung disease, lung transplantation, sleep and ventilation, severe asthma, allergy and pulmonary infection. Thoracic Surgery The department is fully committed to an integrated academic/clinical service and instrumental in the success of lung cancer tissue banking. It is supported by 5 Consultant Thoracic Surgeons. 18 Thoracic Medical Oncology The department has 3 Consultant Medical Oncologists specialising in adjuvant therapy for NSCLC, systemic treatment of advanced lung cancer and malignant pleural mesothelioma. They are responsible for a large portfolio of clinical trials and are nationally leading in clinical trial recruitment. Thoracic Pathology The NWLC is supported by the regional department of thoracic pathology. The department is supportive of a broad range of research studies, from tissue banking to trial specific procedures. Specialist Thoracic Radiology This is currently provided by 3 Consultants. I) Terms and Conditions of Service (NHS) Pay The salary details for this post are based on the New NHS Consultant Contract Terms and Conditions. The post holder will have an honorary contract with The Christie subject to appropriate verification of qualifications. The post is subject to the receipt of satisfactory references and a DBS check. The post holder must be in possession of Full Registration with the General Medical Council and be on the Specialist Register. Confidentiality The post holder must maintain the confidentiality of information about patients, staff and other health service business. Health and Safety Employees must be aware of the responsibilities placed on them under the Health & Safety at Work Act (1974) and ensure that the agreed safety procedures are carried out to maintain a safe environment for employees. Risk Management All staff have a responsibility to report all clinical and non-clinical accidents or incidents promptly and when requested to co-operate with any investigation undertaken. Equal Opportunities The Christie has adopted an equal opportunities policy and it is the duty of every employee to comply with the detail and spirit of the policy. Conflict of Interest The Christie is responsible for the service for the patients in its care to ensure it meets the highest standards. Equally, it is responsible for ensuring that staff do not abuse their official position to gain or to benefit their family or friends. The Christie’s standing orders require any officer to declare any interest, direct or indirect, with contracts involving the Trust. Staff are not allowed to further their private interest in the course of their NHS duties. No Smoking 19 The Trust operates a no smoking policy. Medical Examination All appointments with The Christie are subject to pre-employment health screening. 20 J) APPENDIX 1 - Medical Oncology Consultant Staff NAME Professor Robert Hawkins Professor Tony Howell Professor Gordon Jayson Professor John Radford Professor Malcolm Ranson Dr Paul Lorigan Dr Fiona Blackhall Dr Fiona Thistlethwaite Dr Juan Valle Dr Andrew Wardley Dr Greg Wilson Dr Jurjees Hassan Dr Michael Leahy Dr Was Mansoor Dr Saifee Mullamitha Dr Anne Armstrong Dr Paul Taylor Dr Yvonne Summers Dr Dr Dr Dr Dr Dr Dr Dr Mike Braun Andrew Clamp Kim Linton Raffael Callifano Sacha Howell Richard Hubner Emma Dean Claire Mitchell PRINCIPAL INTEREST(S) Renal, Gastric and Immunotherapy Phase I Trials Breast cancer prevention Ovarian Cancer and Anti-Angiogenesis Phase I Trials Lymphoma Clinical Pharmacology, Phase I trials Melanoma and Lung Cancer Lung Cancer Upper GI Hepatobiliary and Neuroendocrine Breast Cancer Breast and Colorectal Cancer Colorectal and Ovarian Sarcoma and Teratoma Oesophago-Gastric/NET, Education Colorectal Cancer – link with Pennine Trust Breast cancer – linking with Crewe Lung -linking with University Hospital of South Manchester NHS Foundation Trust Lung- Linking with University Hospital of South Manchester NHS Foundation Trust Colorectal Gynaecologic Cancer Lymphoma Lung Cancer Breast Gastrointestinal Clinical Pharmacology Gynaecological Cancer 21 K) APPENDIX 2 - Clinical Oncology Consultant Staff NAME Clinical Director - Dr J Logue Professor RA Cowan Professor NJ Slevin Dr PA Burt Dr A Chittalia Dr C Coyle Dr A Choudhury Dr SE Davidson Dr T Elliott Dr C Faivre-Finn Dr HR Gattamaneni Dr M Harris Dr L Barraclough Professor T Illidge Dr L Bhatt Dr L Lee Dr JE Livsey Dr J Loncaster Dr B Magee Dr V Misra Dr C McBain Dr J Coote Dr H Lander Dr M Saunders Dr H Sheikh Dr E Smith Dr L Pemberton Dr A Sykes Dr R S Welch Dr J Wylie Dr B Yap Dr E Allan (part time) Dr N Alam Dr A Tran Dr C Arthur PERIPHERAL CLINIC SERVICE Stockport PRINCIPAL INTEREST(S) Genito-Urinary Wigan Lymphoma Crewe/MRI Stockport Stockport Oldham Salford MDT Bolton/Salford Salford/Children’s Hospital Tameside Macclesfield Tameside Bury/NMGH Oldham/St Marys NMGH Salford Oldham Macclesfield/Salford Oldham Oldham Salford/Wythenshawe Salford/Macclesfield North Manchester Children’s Hospital Oldham Tameside Bolton/Salford Royal Crewe/South Manchester Head & Neck Lung Breast/Lung GU/Sarcoma GU Gynaecology Urology Lung CNS/Paeds Lung/Lymphoma Breast/Gynaecology Lymphoma Breast/Oesophagus Head & Neck/Lung Gynaecology/Urology Breast Breast Breast/Colorectal Colorectal/CNS Breast/Lung Breast Gastrointestinal Lung/Oesophagus Lymphoma/Paediatric/Young Adult Lung Head & Neck/Melanoma Ovarian/Testicular/Breast GU/Sarcoma Thyroid/Head & Neck PDT for Skin Cancer Bolton/Salford/Stockport/Pennine Gastrointestinal/GU Acute Salford CNS/GU Salford Colorectal / Thyroid 22 L) APPENDIX 3 - The Christie NHS Foundation Trust Executive Board NAME Caroline Shaw Joanne Fitzpatrick Tony Blower Jackie Bird Roger Spencer ROLE Chief Executive Director of Finance & Business Planning Medical Director Director of Nursing and Quality Chief Operating Officer 23